Catalog No.: PC-49202Not For Human Use, Lab Use Only.
AMD3465 (AMD 3465) is a potent, selective monomacrocyclic CXCR4 antagonist with IC50 of 0.75 nM for inhibition of 12G5 mAb binding to CXCR4, dose-dependently inhibits CXCL12 binding in SupT1 cells with IC50 of 18 nM.
AMD3465 (AMD 3465) is a potent, selective monomacrocyclic CXCR4 antagonist with IC50 of 0.75 nM for inhibition of 12G5 mAb binding to CXCR4, dose-dependently inhibits CXCL12 binding in SupT1 cells with IC50 of 18 nM.
AMD3465 inhibits CXCL12-induced calcium signaling in SupT1 cells with IC50 of 17 nM, AMD3465 is >10-fold more potent than AMD3100 in inhibiting calcium mobilization with IC50 of 4 and 58 nM, respectively.
AMD3465 completely failed to block the intracellular calcium fluxes elicited by the CCR5 ligands RANTES, LD78b and MIP-1b in U87.CD4.CCR5 cells.
AMD3465 dose-dependently inhibits intracellular calcium signaling, chemotaxis, CXCR4 endocytosis and mitogen-activated protein kinase phosphorylation induced by CXCL12.
AMD3465 is highly potent against X4 HIV strains (IC50=1-10 nM).
AMD3465 specifically blocks the interaction of HIV gp120 with CXCR4.
